日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Curcumin for Inflammation Control in Individuals with Type 2 Diabetes Mellitus and Metabolic Dysfunction-Associated Steatotic Liver Disease: A Randomized Controlled Trial.

姜黄素对 2 型糖尿病和代谢功能障碍相关脂肪肝患者的炎症控制作用:一项随机对照试验

Yaikwawong Metha, Jansarikit Laddawan, Jirawatnotai Siwanon, Chuengsamarn Somlak

Curcumin Reduces Depression in Obese Patients with Type 2 Diabetes: A Randomized Controlled Trial

姜黄素可减轻肥胖型2型糖尿病患者的抑郁症状:一项随机对照试验

Yaikwawong, Metha; Jansarikit, Laddawan; Jirawatnotai, Siwanon; Chuengsamarn, Somlak

The Effect of Curcumin on Reducing Atherogenic Risks in Obese Patients with Type 2 Diabetes: A Randomized Controlled Trial

姜黄素对降低2型糖尿病肥胖患者动脉粥样硬化风险的影响:一项随机对照试验

Yaikwawong, Metha; Jansarikit, Laddawan; Jirawatnotai, Siwanon; Chuengsamarn, Somlak

Immunogenicity of BNT162b2 as a first booster after a ChAdOx1 primary series in a Thai geriatric population living with frailty

在泰国体弱老年人群中,BNT162b2 作为 ChAdOx1 基础免疫系列后的首次加强免疫的免疫原性

Niyomnaitham, Suvimol; Chokephaibulkit, Kulkanya; Pheerapanyawaranun, Chatkamol; Toh, Zheng Quan; Licciardi, Paul V; Satayasanskul, Arpa; Jansarikit, Laddawan; Assantachai, Prasert

Curcumin extract improves beta cell functions in obese patients with type 2 diabetes: a randomized controlled trial

姜黄素提取物可改善肥胖型 2 型糖尿病患者的 β 细胞功能:一项随机对照试验

Yaikwawong, Metha; Jansarikit, Laddawan; Jirawatnotai, Siwanon; Chuengsamarn, Somlak

Immunogenicity and safety of tixagevimab-cilgavimab for COVID-19 pre-exposure prophylaxis in immunocompromised 20 to <40 kg children and adolescents: A pilot, prospective, open-labeled study

tixagevimab-cilgavimab 用于 COVID-19 暴露前预防在免疫功能低下(体重 20 至 <40 kg)的儿童和青少年中的免疫原性和安全性:一项前瞻性、开放标签的试点研究

Buaboonnam, Jassada; Rungmaitree, Supattra; Piyaphanee, Nuntawan; Charuvanij, Sirirat; Pitisuttithum, Onsiri; Copeland, Katherine; Pheerapanyawaranun, Chatkamol; Jansarikit, Laddawan; Niyomnaitham, Suvimol; Chokephaibulkit, Kulkanya

Immunogenicity and reactogenicity of heterologous COVID-19 vaccination in pregnant women

异源性新冠疫苗在孕妇中的免疫原性和反应原性

Chayachinda, Chenchit; Watananirun, Kanokwaroon; Phatihattakorn, Chayawat; Anuwutnavin, Sanitra; Niyomnaitham, Suvimol; Phongsamart, Wanatpreeya; Lapphra, Keswadee; Wittawatmongkol, Orasri; Rungmaitree, Supattra; Jansarikit, Laddawan; Boonnak, Kobporn; Wongprompitak, Patimaporn; Senawong, Sansnee; Upadhya, Avishek; Toh, Zheng Quan; Licciardi, Paul V; Chokephaibulkit, Kulkanya

Immunogenicity and reactogenicity of accelerated regimens of fractional intradermal COVID-19 vaccinations

分次皮内注射COVID-19疫苗加速方案的免疫原性和反应原性

Niyomnaitham, Suvimol; Atakulreka, Suparat; Wongprompitak, Patimaporn; Copeland, Katherine Kradangna; Toh, Zheng Quan; Licciardi, Paul V; Srisutthisamphan, Kanjana; Jansarikit, Laddawan; Chokephaibulkit, Kulkanya

Immunogenicity and reactogenicity against the SARS-CoV-2 variants following heterologous primary series involving CoronaVac, ChAdox1 nCov-19 and BNT162b2 plus BNT162b2 booster vaccination: An open-label randomized study in healthy Thai adults

一项在健康泰国成年人中进行的开放标签随机研究,旨在评估异源性基础免疫接种(包括CoronaVac、ChAdox1 nCov-19和BNT162b2疫苗)以及BNT162b2加强免疫接种对SARS-CoV-2变异株的免疫原性和反应原性。

Niyomnaitham, Suvimol; Quan Toh, Zheng; Wongprompitak, Patimaporn; Jansarikit, Laddawan; Srisutthisamphan, Kanjana; Sapsutthipas, Sompong; Jantraphakorn, Yuparat; Mingngamsup, Natthakarn; Licciardi, Paul V; Chokephaibulkit, Kulkanya